$XBI $129 -2%
Want to access our searchable database of over 900 catalyst events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Covid Updates
$RDHL +9% Phase 2/3 COVID-19 Opaganib study unanimously recommended to continue. source
$CYDY +1% Leronlimab long-haulers trial closed with full enrollment. source
Pipeline Updates
$SRNE -3% Received sNDA approval from FDA for ZTlido. source
$MRSN -2% Phase 2 UPLIFT trial of UpRi initiates patient dosing. source
$RUBY -1% Phase 1/2 trial of RTX-240 reported positive data and initiating new Phase 1 arm. source
$HGEN +3% Phase 1 ifabotuzumab results reported at AACR 2021. source
$GLSI +9% Phase 2b 5 year immune response reported 0% cancer recurrences. source